We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
Read MoreHide Full Article
On May 12, Gilead Sciences, Inc. (GILD - Free Report) entered into an agreement with five generic drugmakers to make antiviral drugs in 127 countries, not including the United States. The agreement will allow these drugmakers to manufacture and distribute remdesivir in low-income countries. The deal is royalty free.
Biotechnology companies and drugmakers across the world are leaving no stone unturned to develop a vaccine for the deadly COVID-19. Also, pharmaceutical giants are speeding up vaccine development for the novel coronavirus. Although the FDA is yet to approve a drug or treatment for COVID-19, company has already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Gilead Ramps Up Remdesivir Manufacturing
Gilead said that the deal with the five generic drug manufacturers — Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — is royalty free. This is so until the World Health Organization says the Covid-19 outbreak is no longer a global health crisis or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent the virus, whichever is earlier.
Earlier this month, the FDA granted emergency use authorization for Gilead’s remdesivir to treat COVID-19. Remdesivir, an intravenous drug, has so far shown promise by helping in shortening the recovery time of some hospitalized Covid-19 patients, new clinical trial data suggests.
Pharma and Biotech Giants Lead the COVID-19 Fight
A number of biotech companies and pharmaceutical giants have joined forces to fight the coronavirus that has infected more than 4 million people globally over the past four months. This has seen many big names collaborating on both development and manufacturing of vaccines and drugs.
On May 12, Moderna, Inc. (MRNA - Free Report) said that its experimental COVID-19 vaccine has gained Fast Track designation from the FDA. Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need.
Last month, Sanofi (SNY - Free Report) and GlaxoSmithKline plc (GSK - Free Report) collaborated to expedite the development of a vaccine for the Wuhan virus. Sanofi recently said that if successful, the vaccine would be available in the second half of 2021. Also, German pharmaceutical giant Pfizer, Inc. (PFE - Free Report) , which is working in collaboration with BioNTech SE (BNTX - Free Report) , recently said that a coronavirus vaccine could be ready for emergency use as early as September.
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccines they are working on. Pfizer is reportedly contemplating shifting more of its medicine production to outside contractors, as it is focusing on large-scale production of its experimental COVID-19 vaccine, provided it proves effective in curing the disease.
Earlier this month, Moderna said that it could start manufacturing its yet-unconfirmed COVID-19 vaccine as early as July after it entered a 10-year deal with Swiss contract drugmaker Lonza to ramp up production of the experimental coronavirus vaccine.
Our Choices
A lot of money is being pumped in by biotech companies and drugmakers in research and development of a vaccine to treat the novel coronavirus. Below are five biotech stocks that are set to rally in the near future.
Regeneron Pharmaceuticals Inc (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments targeting serious medical conditions.
The company’s expected earnings growth rate for the current year is 11.6%. The stockhas rallied 8.7% in the past 30 days. Regeneron has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
GlaxoSmithKline plc has three core businesses – Pharmaceuticals (respiratory, HIV, immuno-inflammation and oncology), Vaccines (meningitis, shingles and influenza vaccines) and Consumer Healthcare (oral health, wellness, skin health and nutrition products).
The company’s expected earnings growth rate for the next year is 1%. The stock has gained 8.6% over the past 30 days. GlaxoSmithKline carries a Zacks Rank #2.
Gilead is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV), liver diseases, hematology and oncology diseases, and inflammation and respiratory diseases.
TheZacks Rank #2company’s expected earnings growth rate for the next year is 1.4%. Its shares have rallied 6% in the past 30 days.
CytoDyn Inc (CYDY - Free Report) is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection.
CytoDyn’s expected earnings growth rate for the current year is 4.8%. The company’s shares have rallied 11.1% in the past 30 days. CytoDyn carries a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
On May 12, Gilead Sciences, Inc. (GILD - Free Report) entered into an agreement with five generic drugmakers to make antiviral drugs in 127 countries, not including the United States. The agreement will allow these drugmakers to manufacture and distribute remdesivir in low-income countries. The deal is royalty free.
Biotechnology companies and drugmakers across the world are leaving no stone unturned to develop a vaccine for the deadly COVID-19. Also, pharmaceutical giants are speeding up vaccine development for the novel coronavirus. Although the FDA is yet to approve a drug or treatment for COVID-19, company has already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Gilead Ramps Up Remdesivir Manufacturing
Gilead said that the deal with the five generic drug manufacturers — Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — is royalty free. This is so until the World Health Organization says the Covid-19 outbreak is no longer a global health crisis or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent the virus, whichever is earlier.
Earlier this month, the FDA granted emergency use authorization for Gilead’s remdesivir to treat COVID-19. Remdesivir, an intravenous drug, has so far shown promise by helping in shortening the recovery time of some hospitalized Covid-19 patients, new clinical trial data suggests.
Pharma and Biotech Giants Lead the COVID-19 Fight
A number of biotech companies and pharmaceutical giants have joined forces to fight the coronavirus that has infected more than 4 million people globally over the past four months. This has seen many big names collaborating on both development and manufacturing of vaccines and drugs.
On May 12, Moderna, Inc. (MRNA - Free Report) said that its experimental COVID-19 vaccine has gained Fast Track designation from the FDA. Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need.
Last month, Sanofi (SNY - Free Report) and GlaxoSmithKline plc (GSK - Free Report) collaborated to expedite the development of a vaccine for the Wuhan virus. Sanofi recently said that if successful, the vaccine would be available in the second half of 2021. Also, German pharmaceutical giant Pfizer, Inc. (PFE - Free Report) , which is working in collaboration with BioNTech SE (BNTX - Free Report) , recently said that a coronavirus vaccine could be ready for emergency use as early as September.
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccines they are working on. Pfizer is reportedly contemplating shifting more of its medicine production to outside contractors, as it is focusing on large-scale production of its experimental COVID-19 vaccine, provided it proves effective in curing the disease.
Earlier this month, Moderna said that it could start manufacturing its yet-unconfirmed COVID-19 vaccine as early as July after it entered a 10-year deal with Swiss contract drugmaker Lonza to ramp up production of the experimental coronavirus vaccine.
Our Choices
A lot of money is being pumped in by biotech companies and drugmakers in research and development of a vaccine to treat the novel coronavirus. Below are five biotech stocks that are set to rally in the near future.
Regeneron Pharmaceuticals Inc (REGN - Free Report) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments targeting serious medical conditions.
The company’s expected earnings growth rate for the current year is 11.6%. The stockhas rallied 8.7% in the past 30 days. Regeneron has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
GlaxoSmithKline plc has three core businesses – Pharmaceuticals (respiratory, HIV, immuno-inflammation and oncology), Vaccines (meningitis, shingles and influenza vaccines) and Consumer Healthcare (oral health, wellness, skin health and nutrition products).
The company’s expected earnings growth rate for the next year is 1%. The stock has gained 8.6% over the past 30 days. GlaxoSmithKline carries a Zacks Rank #2.
Gilead is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV), liver diseases, hematology and oncology diseases, and inflammation and respiratory diseases.
TheZacks Rank #2company’s expected earnings growth rate for the next year is 1.4%. Its shares have rallied 6% in the past 30 days.
CytoDyn Inc (CYDY - Free Report) is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection.
CytoDyn’s expected earnings growth rate for the current year is 4.8%. The company’s shares have rallied 11.1% in the past 30 days. CytoDyn carries a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>